Literature DB >> 1203840

Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.

P Seifert, L H Baker, M L Reed, V K Vaitkevicius.   

Abstract

In a randomized series of 70 patients with with colo rectal adenocarcinoma, a comparison of systemic 5-fluorouracil chemotherapy administered as a continuous 120-hours infusion vs. intravenous bolus injection daily for 5 days demonstrated superiority of prolonged intravenous infusion. The most striking advantage of prolonged infusion of 5-FU was the absence of myelotoxicity. Fifteen of the 34 patients treated with infusion and 8 of the 36 patients treated by bolus injection developed objective tumor responses. The difference in response rate at least in part is explainable by unequal distribution of patients with different characteristics between the two treatment groups.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1203840     DOI: 10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  66 in total

1.  Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.

Authors:  C J Fabian; R Molina; M Slavik; S Dahlberg; S Giri; R Stephens
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

Review 2.  Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.

Authors:  R L Poorter; P J Bakker; C H Veenhof
Journal:  Pharm World Sci       Date:  1998-04

Review 3.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

4.  High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells.

Authors:  Yi-Shing Ma; I-Ping Yang; Hsiang-Lin Tsai; Ching-Wen Huang; Suh-Hang Hank Juo; Jaw-Yuan Wang
Journal:  DNA Cell Biol       Date:  2013-11-27       Impact factor: 3.311

Review 5.  Cellular pharmacology of fluorinated pyrimidines in vivo in man.

Authors:  J S Kovach; R W Beart
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

Review 6.  Cancer of the esophagus: the Wayne State University experience.

Authors:  L Leichman
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

Review 7.  Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.

Authors:  M al-Sarraf
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

8.  Effect of acyclovir on radiation- and chemotherapy-induced mouth lesions.

Authors:  G J Bubley; B Chapman; S K Chapman; C S Crumpacker; L E Schnipper
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 9.  5-Fluorouracil radiation sensitization--a brief review.

Authors:  J E Byfield
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

10.  Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer.

Authors:  E A Poplin; P LoRusso; J J Lokich; J J Gullo; P D Leming; J J Schulz; S R Veach; W McCulloch; L Baker; P Schein
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.